Vivos (RDGL) Liabilities and Shareholders Equity (2010 - 2025)
Vivos (RDGL) posted Liabilities and Shareholders Equity of $1.9 million for Q4 2025, down 18.63% sequentially from $2.3 million in Q3 2025, and down 16.38% YoY from $2.2 million in Q4 2024.
Vivos (RDGL) Liabilities and Shareholders Equity (2010 - 2025) Analysis & Trends
Vivos has reported Liabilities and Shareholders Equity for 16 years, with the latest figure at $1.9 million in Q4 2025.
- Quarterly Liabilities and Shareholders Equity fell 16.38% year-over-year to $1.9 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $10.2 million (up 54.46% YoY) and the FY2025 annual result came in at $1.9 million, down 16.38% from the prior year.
- Liabilities and Shareholders Equity declined to $1.9 million in Q4 2025 per RDGL's latest filing, from $2.3 million in the prior quarter.
- Over five years, Liabilities and Shareholders Equity peaked at $3.3 million in Q1 2025 and troughed at $1.1 million in Q2 2022.
- A 5-year average of $1.9 million and a median of $1.8 million in 2023 frame the typical range for Liabilities and Shareholders Equity.
- The sharpest annual moves came in 2021 and 2022: Liabilities and Shareholders Equity jumped 3429.68% in 2021, then tumbled 50.37% in 2022.
- Over 5 years, Liabilities and Shareholders Equity stood at $1.6 million in 2021, then advanced by 6.64% to $1.7 million in 2022, then declined by 7.61% to $1.6 million in 2023, then surged by 38.71% to $2.2 million in 2024, then slipped by 16.38% to $1.9 million in 2025.
- According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $1.9 million, $2.3 million, and $2.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 198.70 Bn | 193.10 Bn | 7.27 Bn | 109.22 Bn |
| 2 | Stryker | 125.85 Bn | 122.37 Bn | 4.50 Bn | 47.93 Bn |
| 3 | Medtronic | 118.44 Bn | 109.22 Bn | 6.41 Bn | 93.03 Bn |
| 4 | Boston Scientific | 72.64 Bn | 72.10 Bn | 3.85 Bn | 45.22 Bn |
| 5 | Edwards Lifesciences | 51.94 Bn | 47.69 Bn | 1.35 Bn | 13.87 Bn |
| 6 | Dexcom | 34.48 Bn | 32.53 Bn | 830.00 Mn | 6.46 Bn |
| 7 | GE HealthCare Technologies | 33.60 Bn | 31.49 Bn | 2.18 Bn | 37.25 Bn |
| 8 | Koninklijke Philips | 26.30 Bn | 22.98 Bn | 4.55 Bn | 31.04 Bn |
| 9 | Steris | 23.00 Bn | 22.52 Bn | 684.20 Mn | 10.74 Bn |
| 10 | Vivos | 24.08 Mn | 22.53 Mn | -3,105.00 | 1.87 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 1.87 Mn |
| Sep 30, 2025 | 2.30 Mn |
| Jun 30, 2025 | 2.78 Mn |
| Mar 31, 2025 | 3.30 Mn |
| Dec 31, 2024 | 2.23 Mn |
| Sep 30, 2024 | 1.24 Mn |
| Jun 30, 2024 | 1.77 Mn |
| Mar 31, 2024 | 1.38 Mn |
| Dec 31, 2023 | 1.61 Mn |
| Sep 30, 2023 | 1.57 Mn |
| Jun 30, 2023 | 1.79 Mn |
| Mar 31, 2023 | 1.46 Mn |
| Dec 31, 2022 | 1.74 Mn |
| Sep 30, 2022 | 2.05 Mn |
| Jun 30, 2022 | 1.11 Mn |
| Mar 31, 2022 | 1.31 Mn |
| Dec 31, 2021 | 1.63 Mn |
| Sep 30, 2021 | 2.04 Mn |
| Jun 30, 2021 | 2.23 Mn |
| Mar 31, 2021 | 2.52 Mn |